CoChat

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Persistent mTORC1 signaling correlates with resistance to PI3K p110α inhibition in breast cancer, which can be overcome by inhibiting mTORC1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3005747

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 51 references

Research works printed but not linked: 1

  1. Kim P. S., Von Ahsen O., Schmitz A., Schatz C., Magonova K., Lee T., Harvie G., Barham R., Leesman G., Kuller A., Lin F., Gong H., Krahn T., Singh S., Pathway profiling of signal transduction proteins in paired tumor and adjacent normal tissues obtained from breast cancer patients. Cancer Res. 70 (2010).

Cited by

See all 355

Metadata

Authors
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., Engelman, J. A., Scaltriti, M., & Baselga, J.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Massachusetts General Hospital (US)
  • Harvard University (US)
  • Vall d'Hebron Institute of Oncology (ES)
  • Prometheus Therapeutics & Diagnostics, 9410 Carroll Park Drive, San Diego, CA 92121, USA.
  • Novartis (Switzerland) (CH)
  • Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Human Oncology & Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
Corresponding author
Scaltriti, Maurizio
Venue
Science Translational Medicine
Published
2013-07-31
Volume
5
Issue
196
Pages
196ra99-196ra99
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2153096480
Cited by
332
References
50
Citations by year
2026: 10 · 2025: 12 · 2024: 33 · 2023: 18 · 2022: 13 · 2021: 34 · 2020: 33 · 2019: 32 · 2018: 16 · 2017: 27 · 2016: 34 · 2015: 34 · 2014: 29 · 2013: 7
FWCI
15.54
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
National Cancer Institute (K99CA180221, R01CA137008)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
mTORC1 inhibition, PIK3CA mutation, breast cancer, alpelisib, everolimus, drug resistance, Akt phosphorylation, insulin-like growth factor I, neuregulin-1, combination therapy, mTOR signaling
MeSH terms
Everolimus, Mechanistic Target of Rapamycin Complex 1, Phosphoinositide-3 Kinase Inhibitors, Adult, Animals, Breast Neoplasms, Female, Humans, Insulin-Like Growth Factor I, Middle Aged, Mutation, Treatment Outcome, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Sirolimus, Inhibitory Concentration 50, Neuregulin-1, Ribosomal Protein S6, Cell Line, Tumor, Multiprotein Complexes, Protein Kinase Inhibitors, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer. https://app.cochat.ai/papers/10.1126/scitranslmed.3005747
The paper
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., . . . Baselga, J. (2013). mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3005747

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.